The
Latest

back to news >

Our bench strength is in our extensive experience and team approach. We strive to facilitate each of our client’s needs through strategy, research, and collaboration.

December 2, 2022

Cognitive Research Corporation Names Mike Trudnak Chief Information Officer

Cognitive Research Corporation (CRC) announces that Mike Trudnak has joined the company in the role of Chief Information Officer, effective November 2022. CRC has been supporting clinical development for CNS-focused small to mid-size pharma, biotech, and medical device companies for over 16 years. The company has experienced explosive growth over the past several years, recently closing a growth equity and recapitalization investment from RC Capital.

Mr. Trudnak is a seasoned IT executive who brings over 25 years of experience leading small to large scale organizations and developing top-tier global teams in the clinical research industry. He has experience in both niche and full-service CROs providing security and compliance consultative services to life services companies. As CIO, Mr. Trudnak will provide strategic planning capabilities that enable rapid and efficient business transformations, fueling innovation, and helping improve all facets of IT and business operations.

“I have known Mike for many years and value his intellect and broad perspectives on technology and the evolving clinical development landscape. Mike is joining a solid team and I am confident he will be a key leader in our continued growth to meet our client’s needs,” says C.G. (Chip) Gillooly, Chief Executive Officer of CRC.

About Cognitive Research Corporation
Cognitive Research Corporation’s mission is to support innovative companies developing new medicines and therapies to improve mental health and neurological disorders.  As a leading neuroscience clinical research organization (CRO) and cognitive assessment technology company, CRC works with sponsors, specialized clinical trial sites, and CNS experts to bring new drugs through rigorous testing to support FDA submissions and eventual market introduction. For more information, visit www.cogres.com.